This Article Figures Only Full Text Full Text (PDF) All Versions of this Article: j.jacc.2006.02.057v1 48/1/161    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jux, C. Articles by Paul, T. Search for Related Content PubMed PubMed Citation Articles by Jux, C. Articles by Paul, T.

CLINICAL RESEARCH: CONGENITAL HEART DISEASE

Interventional Atrial Septal Defect Closure Using a Totally Bioresorbable Occluder Matrix

Development and Preclinical Evaluation of the BioSTAR Device

Christian Jux, MD^_*,_*, Harald Bertram, MD, Peter Wohlsein, DVM, Michael Bruegmann, DVM and Thomas Paul, MD, FACC^_*

^_* Departments of Pediatric Cardiology and Pediatric Intensive Care Medicine, Georg-August University, Goettingen, Germany
Hannover Medical School, Hannover, Germany
Institute of Pathology, School of Veterinary Medicine, Hannover, Germany

Manuscript received October 17, 2005; revised manuscript received February 9, 2006, accepted February 14, 2006.

^_* Reprint requests and correspondence: Dr. Christian Jux, Department of Pediatric Cardiology and Pediatric Intensive Care Medicine, Georg-August University, Robert Koch Strasse 40, D-37099 Goettingen, Germany (Email: Dr.C.Jux{at}medizin.uni-goettingen.de).

OBJECTIVES: We sought to test the hypothesis that interventional atrial septal defect (ASD) closure can be performed safely and effectively using a bioresorbable occluder matrix.

BACKGROUND: The ideal septal occluder scaffold should promote the healthiest and most complete healing response while eventually facilitating the full resorption of the material and leaving "native" tissue behind, thus minimizing the potential for future complications from chronic foreign body and maintaining the possibility for later unobstructed transseptal access to the left atrium.

METHODS: The STARFlex occluders (NMT Medical Inc., Boston, Massachusetts) were modified by substituting the conventional polyester fabric for a bioengineered, acellular type-I collagen matrix derived from porcine submucosa with a heparin-coated surface (BioSTAR occluder, NMT Medical Inc.). Comparative transcatheter closure of ASDs was performed in young sheep (n = 36). Gross pathology and histopathology were obtained after follow-up periods ranging from 7 days to 2 years.

RESULTS: The STARFlex (control) devices were encapsulated time-dependently by ingrown fibrous tissue. Histology showed a mild but chronically persisting foreign body reaction. By contrast, BioSTAR devices exhibited a mild-to-moderate transient cellular immune response. Heparin coating of the BioSTAR surface improved the biocompatibility of the device by reducing surface thrombogencity. A remodeling process of the collagen scaffold, starting after 30 days in vivo, resulted in the full replacement of the matrix by host tissue after 2 years of follow-up.

CONCLUSIONS: The BioSTAR device is the first septal occluder with a totally bioresorbable matrix that is fully replaced by host tissue during the healing process. The promising results of this study support testing of the BioSTAR device in clinical trials.

Abbreviations and Acronyms   ASD = atrial septal defect   ICE = intracardiac echocardiography   ICL = intestinal collagen layer

This article has been cited by other articles:

				M. Cikirikcioglu, S. Cherian, R. Lerch, M.-J. Licker, M. Roffi, R. F. Bonvini, and A. Kalangos Late Tamponade Secondary to Aortic Root Perforation by BioSTAR Septal Closure Device Ann. Thorac. Surg., February 1, 2011; 91(2): 604 - 606. [Abstract] [Full Text] [PDF]

				B. J. Van den Branden, M. C. Post, H. W. Plokker, J. M. ten Berg, and M. J. Suttorp Patent Foramen Ovale Closure Using a Bioabsorbable Closure Device: Safety and Efficacy at 6-Month Follow-Up J. Am. Coll. Cardiol. Intv., September 1, 2010; 3(9): 968 - 973. [Abstract] [Full Text] [PDF]

				R. S. Schwartz, D. R. Holmes, R. A. Van Tassel, R. Hauser, T. D. Henry, M. Mooney, R. Matthews, S. Doshi, R. M. Jones, and R. Virmani Left Atrial Appendage Obliteration: Mechanisms of Healing and Intracardiac Integration J. Am. Coll. Cardiol. Intv., August 1, 2010; 3(8): 870 - 877. [Abstract] [Full Text] [PDF]

				H. Hara, T. K. Jones, E. R. Ladich, R. Virmani, D. C. Auth, J. E. Eichinger, R. J. Sommer, R. A. Van Tassel, and R. S. Schwartz Patent Foramen Ovale Closure by Radiofrequency Thermal Coaptation: First Experience in the Porcine Model and Healing Mechanisms Over Time Circulation, August 7, 2007; 116(6): 648 - 653. [Abstract] [Full Text] [PDF]

				A. N. DeMaria, O. Ben-Yehuda, G. K. Feld, G. S. Ginsburg, B. H. Greenberg, W. Y.W. Lew, J. A.C. Lima, A. S. Maisel, J. Narula, D. J. Sahn, et al. Highlights of the Year in JACC 2006 J. Am. Coll. Cardiol., January 30, 2007; 49(4): 509 - 527. [Full Text] [PDF]

				M. J. Mullen, D. Hildick-Smith, J. V. De Giovanni, C. Duke, W. S. Hillis, W. L. Morrison, and C. Jux BioSTAR Evaluation STudy (BEST): A Prospective, Multicenter, Phase I Clinical Trial to Evaluate the Feasibility, Efficacy, and Safety of the BioSTAR Bioabsorbable Septal Repair Implant for the Closure of Atrial-Level Shunts Circulation, October 31, 2006; 114(18): 1962 - 1967. [Abstract] [Full Text] [PDF]